Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor

BACKGROUND: Cipatinib is a novel tyrosine kinase inhibitor against both EGFR and HER2/neu. This phase I trial was conducted to assess the safety, dose‐limiting toxicities (DLTs), and maximum‐tolerated dose of cipatinib in HER2‐positive patients with advanced breast cancer. METHODS: Eligible adults w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiayu, Han, Yiqun, Shi, Xiuqing, Li, Qing, Zhang, Pin, Yuan, Peng, Ma, Fei, Luo, Yang, Cai, Ruigang, Fan, Ying, Chen, Shanshan, Li, Qiao, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068438/
https://www.ncbi.nlm.nih.gov/pubmed/29893055
http://dx.doi.org/10.1111/1759-7714.12784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068438/
https://www.ncbi.nlm.nih.gov/pubmed/29893055
http://dx.doi.org/10.1111/1759-7714.12784

Ejemplares similares